CytokineticsCYTK
Market Cap: $6.36B
About: Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Employees: 564
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
66% more repeat investments, than reductions
Existing positions increased: 154 | Existing positions reduced: 93
54% more call options, than puts
Call options by funds: $199M | Put options by funds: $129M
14.98% more ownership
Funds ownership: 114.16% [Q1] → 129.14% (+14.98%) [Q2]
9% less funds holding in top 10
Funds holding in top 10: 22 [Q1] → 20 (-2) [Q2]
10% less funds holding
Funds holding: 381 [Q1] → 342 (-39) [Q2]
11% less capital invested
Capital invested by funds: $8.24B [Q1] → $7.33B (-$908M) [Q2]
47% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 83
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
9 analyst ratings
JP Morgan Tessa Romero 22% 1-year accuracy 4 / 18 met price target | 31%upside $71 | Overweight Maintained | 5 Sept 2024 |
JMP Securities Jason Butler 55% 1-year accuracy 23 / 42 met price target | 44%upside $78 | Market Outperform Reiterated | 4 Sept 2024 |
HC Wainwright & Co. Joseph Pantginis 31% 1-year accuracy 85 / 271 met price target | 66%upside $90 | Buy Reiterated | 3 Sept 2024 |
Needham Serge Belanger 41% 1-year accuracy 47 / 114 met price target | 33%upside $72 | Buy Reiterated | 3 Sept 2024 |
Goldman Sachs Paul Choi 40% 1-year accuracy 4 / 10 met price target | 11%upside $60 | Neutral Downgraded | 13 Aug 2024 |
Financial journalist opinion
Based on 8 articles about CYTK published over the past 30 days